| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marisol S Castaneto, David A Gorelick, Nathalie A Desrosiers, Rebecca L Hartman, Sandrine Pirard, Marilyn A Huesti. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug and alcohol dependence. vol 144. 2015-10-30. PMID:25220897. |
the majority of sc detected in herbal products have greater binding affinity to the cannabinoid cb1 receptor than does Δ(9)-tetrahydrocannabinol (thc), the primary psychoactive compound in the cannabis plant, and greater affinity at the cb1 than the cb2 receptor. |
2015-10-30 |
2023-08-13 |
human |
| Bruno A Marichal-Cancino, Alain H Altamirano-Espinoza, Guadalupe Manrique-Maldonado, Antoinette MaassenVanDenBrink, Carlos M Villaló. Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats. Basic & clinical pharmacology & toxicology. vol 114. issue 3. 2015-09-28. PMID:24118786. |
administration of antagonists, the inhibition by 3.1 μg/kg min anandamide was: (i) potently blocked by 31-100 μg/kg nida41020 (cb1 ), (ii) unaffected by 180 μg/kg am630 (cb2 ), 31 μg/kg cannabidiol (gpr55) or 31-100 μg/kg capsazepine (trpv1) and (iii) slightly blocked by 310 μg/kg am630. |
2015-09-28 |
2023-08-12 |
rat |
| Brooke Mills, Andres Yepes, Kenneth Nugen. Synthetic Cannabinoids. The American journal of the medical sciences. vol 350. issue 1. 2015-09-08. PMID:26132518. |
although both Δ-tetrahydrocannabinol (thc) and scbs stimulate the same receptors, cannabinoid receptor 1 (cb1) and cannabinoid receptor 2 (cb2), studies have shown that scbs are associated with higher rates of toxicity and hospital admissions than is natural cannabis. |
2015-09-08 |
2023-08-13 |
Not clear |
| D I Abrams, M Guzma. Cannabis in cancer care. Clinical pharmacology and therapeutics. vol 97. issue 6. 2015-08-12. PMID:25777363. |
cannabinoids, the active components of cannabis sativa, mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly cb1 found predominantly in the central nervous system and cb2 found predominantly in cells involved with immune function. |
2015-08-12 |
2023-08-13 |
Not clear |
| Timothy J England, William H Hind, Nadiah A Rasid, Saoirse E O'Sulliva. Cannabinoids in experimental stroke: a systematic review and meta-analysis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 35. issue 3. 2015-04-20. PMID:25492113. |
cannabinoids reduced infarct volume in transient (smd -1.41 (95% ci -1.71), -1.11) p<0.00001) and permanent (-1.67 (-2.08, -1.27), p<0.00001) ischemia and in all subclasses: endocannabinoids (-1.72 (-2.62, -0.82), p=0.0002), cb1/cb2 ligands (-1.75 (-2.19, -1.31), p<0.00001), cb2 ligands (-1.65 (-2.09, -1.22), p<0.00001), cannabidiol (-1.20 (-1.63, -0.77), p<0.00001), Δ(9)-tetrahydrocannabinol (-1.43 (-2.01, -0.86), p<0.00001), and hu-211 (-2.90 (-4.24, -1.56), p<0.0001). |
2015-04-20 |
2023-08-13 |
Not clear |
| Luara A Batista, Pedro H Gobira, Thercia G Viana, Daniele C Aguiar, Fabricio A Moreir. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behavioural pharmacology. vol 25. issue 5-6. 2015-03-31. PMID:25083569. |
the endocannabinoid system comprises the cb1 and cb2 receptors (the targets of the cannabis sativa compound delta-9-tetrahydrocannabinol), the endogenous ligands (endocannabinoids) arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol, their synthesizing machinery and membrane transport system, and the hydrolyzing enzymes fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl), respectively. |
2015-03-31 |
2023-08-13 |
Not clear |
| Daniela Muhl, Markus Kathmann, Carolin Hoyer, Laura Kranaster, Martin Hellmich, Christoph W Gerth, Johannes Faulhaber, Eberhard Schlicker, F Markus Lewek. Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn-Schmiedeberg's archives of pharmacology. vol 387. issue 7. 2015-02-19. PMID:24788457. |
increased cb2 mrna and anandamide in human blood after cessation of cannabis abuse. |
2015-02-19 |
2023-08-13 |
human |
| Daniela Muhl, Markus Kathmann, Carolin Hoyer, Laura Kranaster, Martin Hellmich, Christoph W Gerth, Johannes Faulhaber, Eberhard Schlicker, F Markus Lewek. Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn-Schmiedeberg's archives of pharmacology. vol 387. issue 7. 2015-02-19. PMID:24788457. |
in previous studies, long-term cannabis use led to alterations of the endocannabinoid system including an increase in cb1 and/or cb2 receptor messenger rna (mrna) in blood cells and an increase in the serum level of the endocannabinoid 2-arachidonoyl glycerol. |
2015-02-19 |
2023-08-13 |
human |
| Daniela Muhl, Markus Kathmann, Carolin Hoyer, Laura Kranaster, Martin Hellmich, Christoph W Gerth, Johannes Faulhaber, Eberhard Schlicker, F Markus Lewek. Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn-Schmiedeberg's archives of pharmacology. vol 387. issue 7. 2015-02-19. PMID:24788457. |
in conclusion, marijuana users that had smoked marijuana ≥20 times in their lives and stopped cannabis use at least 6 months before the study show an increase in cb2 receptor mrna in the blood and in serum anandamide level. |
2015-02-19 |
2023-08-13 |
human |
| Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Mical. Therapeutic potential of cannabinoids in schizophrenia. Recent patents on CNS drug discovery. vol 9. issue 1. 2014-12-22. PMID:24605939. |
the endocannabinoid system comprises of two g protein-coupled receptors (the cannabinoid receptors 1 and 2 [cb1 and cb2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [aea] and 2-arachidonoylglycerol [2-ag], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. |
2014-12-22 |
2023-08-12 |
Not clear |
| Robert Ramer, Sascha Fischer, Maria Haustein, Katrin Manda, Burkhard Hin. Cannabinoids inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Biochemical pharmacology. vol 91. issue 2. 2014-10-28. PMID:24976505. |
conditioned media (cm) from a549 lung cancer cells treated with cannabidiol, Δ(9)-tetrahydrocannabinol, r(+)-methanandamide or the cb2 agonist jwh-133 elicited decreased migration as well as tube and sprout formation of huvec as compared to cm of vehicle-treated cancer cells. |
2014-10-28 |
2023-08-13 |
human |
| Emelie Janefjord, Jesper L V Mååg, Benjamin S Harvey, Scott D Smi. Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cellular and molecular neurobiology. vol 34. issue 1. 2014-09-28. PMID:24030360. |
neuroblastoma (sh-sy5y) cells were exposed to aβ1-42 directly or microglial (bv-2 cells) conditioned media activated with lipopolysaccharide (lps) in the presence of the cb1 receptor-selective agonist acea, cb2 receptor-selective agonist jwh-015, phytocannabinoids Δ(9)-thc and cannabidiol (cbd), the endocannabinoids 2-arachidonoyl glycerol (2-ag) and anandamide or putative gpr18/gpr55 ligands o-1602 and abnormal-cannabidiol (abn-cbd). |
2014-09-28 |
2023-08-12 |
Not clear |
| Francisco Espejo-Porras, Javier Fernández-Ruiz, Roger G Pertwee, Raphael Mechoulam, Concepción Garcí. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. vol 75. 2014-08-19. PMID:23924692. |
by contrast, cannabidiol (cbd), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the cb1 and the cb2 receptor, despite its activity at the trpv1 receptor. |
2014-08-19 |
2023-08-12 |
rat |
| Bruno A Marichal-Cancino, Guadalupe Manrique-Maldonado, Alain H Altamirano-Espinoza, Inna Ruiz-Salinas, Abimael González-Hernández, Antoinette Maassenvandenbrink, Carlos M Villaló. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. European journal of pharmacology. vol 721. issue 1-3. 2014-07-15. PMID:24076186. |
the antagonists nida41020 (cb1), am630 (cb2), capsazepine (trpv1) and/or cannabidiol (gpr55). |
2014-07-15 |
2023-08-12 |
rat |
| Sabatino Maione, Barbara Costa, Vincenzo Di Marz. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. vol 154 Suppl 1. 2014-07-03. PMID:23623250. |
after 4 millennia of more or less documented history of cannabis use, the identification of cannabinoids, and of Δ(9)-tetrahydrocannabinol in particular, occurred only during the early 1960s, and the cloning of cannabinoid cb1 and cb2 receptors, as well as the discovery of endocannabinoids and their metabolic enzymes, in the 1990s. |
2014-07-03 |
2023-08-12 |
Not clear |
| Erika Cottone, Valentina Pomatto, Fulvio Cerri, Ezio Campantico, Ken Mackie, Massimiliano Delpero, Alda Guastalla, Claudio Dati, Patrizia Bovolin, Maria Fosca Franzon. Cannabinoid receptors are widely expressed in goldfish: molecular cloning of a CB2-like receptor and evaluation of CB1 and CB2 mRNA expression profiles in different organs. Fish physiology and biochemistry. vol 39. issue 5. 2014-04-07. PMID:23504102. |
cannabinoids, the bioactive constituents of cannabis sativa, and endocannabinoids, among which the most important are anandamide and 2-arachidonoylglycerol, control various biological processes by binding to specific g protein-coupled receptors, namely cb1 and cb2 cannabinoid receptors. |
2014-04-07 |
2023-08-12 |
zebrafish |
| M Ruth Pazos, Nagat Mohammed, Hector Lafuente, Martin Santos, Eva Martínez-Pinilla, Estefania Moreno, Elsa Valdizan, Julián Romero, Angel Pazos, Rafael Franco, Cecilia J Hillard, Francisco J Alvarez, Jose Martínez-Orgad. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology. vol 71. 2014-01-10. PMID:23587650. |
mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5ht(1a) and cb2 receptors. |
2014-01-10 |
2023-08-12 |
Not clear |
| Michelle Sexton, Aurelio Silvestroni, Thomas Möller, Nephi Stell. Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis. Inflammopharmacology. vol 21. issue 3. 2013-12-18. PMID:22492174. |
phytocannabinoids (pcb), the bioactive agents produced by the plant cannabis, regulate the phenotype and function of immune cells by interacting with cb1 and cb2 receptors. |
2013-12-18 |
2023-08-12 |
human |
| E Gaffal, M Cron, N Glodde, T Tütin. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy. vol 68. issue 8. 2013-12-12. PMID:23889474. |
∆(9) -tetrahydrocannabinol (thc), the active constituent of cannabis sativa, exerts its biological effects in part through the g-protein-coupled cb1 and cb2 receptors, which were initially discovered in brain and spleen tissue, respectively. |
2013-12-12 |
2023-08-12 |
mouse |
| Maria J Casarejos, Juan Perucho, Ana Gomez, Maria P Muñoz, Marian Fernandez-Estevez, Onintza Sagredo, Javier Fernandez Ruiz, Manuel Guzman, Justo Garcia de Yebenes, Maria A Men. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. Journal of Alzheimer's disease : JAD. vol 35. issue 3. 2013-10-17. PMID:23478312. |
we tested the effects of sativex®, a mixture of Δ9-tetrahydrocannabinol and cannabidiol, acting on both cb1 and cb2 receptors, in parkin-null, human tau overexpressing (pk-/-/tauvlw) mice, a model of complex frontotemporal dementia, parkinsonism, and lower motor neuron disease. |
2013-10-17 |
2023-08-12 |
mouse |